Venetoclax and azacitidine before a stem cell transplant for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies a combination of two medicines (venetoclax and azacitidine) as a bridge to a stem cell transplant for people with a hard-to-treat type of AML (like secondary AML or with low bone marrow cells). The goal is to get the leukemia under control so a transplant can be done successfully.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of acute myeloid leukemia (AML) that is either just diagnosed or is a secondary type (from a prior blood disorder or after prior chemo/radiation). Your bone marrow must be low in cells or have scarring.
- You must be considered able to have a stem cell transplant (from a donor).
- Your heart, liver, and kidneys must be working reasonably well, and you should be in generally good physical shape.
- You cannot have had any prior treatment for AML (except simple stabilizing measures).
- You cannot have certain 'favorable' gene changes (like NPM1 mutation, CEBPA mutation, t(8;21), or inv(16)).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
Hear when a new Hypoplastic Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.